Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...5152535455565758596061...143144»
  • ||||||||||  Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion date, Trial primary completion date, Metastases:  CAVE: Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer (clinicaltrials.gov) -  Sep 21, 2021   
    P2,  N=77, Active, not recruiting, 
    Trial completion date: Jul 2021 --> Jun 2022 Trial completion date: Jul 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Dec 2021
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Metastatic porocarcinoma: genetic analysis and functional validation identify new therapeutic strategies (Stream 2) -  Sep 20, 2021 - Abstract #ADO2021ADO_449;    
    Intriguingly, the anti-EGFR antibody cetuximab and the MEK inhibitor trametinib showed antitumor activity in a cell line derived from an EPC patient. These observations highlight the potential of genomic profiling and functional validation in identifying novel treatment strategies for rare cancers like EPC.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    PTHrP-induced hypercalcemic psychosyndrome under immune checkpoint blockade in penile squamous cell carcinoma (Stream 4) -  Sep 20, 2021 - Abstract #ADO2021ADO_421;    
    As part of the multicenter, single-arm phase 2 study AliCe for patients with non-resectable cuSCC in stage III / IV, he received therapy with the anti-PD-L1 antibody avelumab (10 mg / kg) in combination with the anti- EGFR antibody cetuximab (500 mg / m2)...Under forced diuresis with furosemide 40 mg, A single dose of pamidronic acid 90 mg and prednisolone 100 mg improved the neurological symptoms...In addition to paraneoplastic hypercalcemia, which is associated with an unfavorable prognosis, immune-mediated hypercalcemia must be discussed in ICI patients. The case also illustrates the need for alternative therapy options for patients with penile cuSCC.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Successive treatment with radiation and immunotherapy results in tumor remission in a patient with advanced CSCC (Stream 5) -  Sep 20, 2021 - Abstract #ADO2021ADO_211;    
    Results : Already one month after starting PD-1 therapy with Cemiplimab, an incipient improvement in the findings and a significant improvement in the general condition could be determined...Conclusion : The successive combination of radiation therapy and PD-1 therapy can represent a valuable treatment option for advanced CSCC. The case underlines the relevance of the close interdisciplinary collaboration between dermatology, radiation oncology and internal oncology in order to achieve a successful therapy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, torkinib (PP242) / Takeda, UCSF Medical Center
    Journal:  A dual-targeted molecular therapy of PP242 and cetuximab plays an anti-tumor effect through EGFR downstream signaling pathways in colorectal cancer. (Pubmed Central) -  Sep 18, 2021   
    We revealed that the combined application of CTX and PP242 can inhibit tumor growth and proliferation by inhibiting the phosphorylation of key molecules in EGFR downstream MEK-ERK and MEK 4/7 (MKK)-c-Jun N-terminal kinase (JNK) signaling pathways in BRAF wild-type CRC cells. In addition, we found that in BRAF mutant CRC cells, the monotherapy of PP242 resulted in negative feedback increased EGFR phosphorylation rates, accompanied by significant up-regulation of downstream MEK and ERK phosphorylation.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Retrospective data, Journal, HEOR, Real-world evidence:  Real-World Treatment Patterns and Outcomes in Patients with Head and Neck Cancer: Point-in-Time Survey of Oncologists in Italy and Spain. (Pubmed Central) -  Sep 17, 2021   
    In addition, we found that in BRAF mutant CRC cells, the monotherapy of PP242 resulted in negative feedback increased EGFR phosphorylation rates, accompanied by significant up-regulation of downstream MEK and ERK phosphorylation. Despite 1L treatment of platinum-eligible patients with R/M SCCHN in Italy and Spain following current European guidelines, patients' QoL remains poor, which highlights the need for alternative treatments that could improve clinical outcomes.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / BMS
    Trial completion date, Metastases:  MCC-19178: Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma (clinicaltrials.gov) -  Sep 16, 2021   
    P1/2,  N=95, Active, not recruiting, 
    Despite 1L treatment of platinum-eligible patients with R/M SCCHN in Italy and Spain following current European guidelines, patients' QoL remains poor, which highlights the need for alternative treatments that could improve clinical outcomes. Trial completion date: Dec 2022 --> Dec 2023
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Journal:  Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer. (Pubmed Central) -  Sep 16, 2021   
    Collectively, our study demonstrated the possibility that miR-193a-3p acts as a tumor suppressor through regulating multiple proteins involved in oncogenesis and affects cellular sensitivity to MAPK-related pathway inhibitors such as BRAF inhibitors, MEK inhibitors, and/or anti-EGFR antibodies. Addition of miR-193a-3p and/or modulation of proteins involved in the miR-193a-3p-mediated pathway, such as Mcl1, to EGFR/BRAF/MEK inhibition may be a potential therapeutic strategy against BRAF-mutated CRC.
  • ||||||||||  Mekinist (trametinib) / Novartis, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Low‑dose trametinib and Bcl‑xL antagonist have a specific antitumor effect in KRAS‑mutated colorectal cancer cells. (Pubmed Central) -  Sep 15, 2021   
    A drug‑screening system (Mix Culture assay) was then applied, revealing that the cells were most sensitive to the MEK inhibitor trametinib among tested drugs, Cetuximab, Panitumumab, Regorafenib, Vemurafenib, BEZ‑235 and Palbociclib...These data suggest that a low dose of trametinib (10 nM), rather than the usual dose of 100 nM, in combination with ABT263 can overcome the resistance to apoptosis induced by Bcl‑xL expression, which occurs concurrently with p‑ERK suppression in KRAS‑mutant cells. This strategy may represent a promising new approach for treating KRAS‑mutant CRC.
  • ||||||||||  ASN007 / Asana BioSci, Erasca, UT MD Anderson Cancer Center
    Enrollment open, Metastases:  HERKULES-3: A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies (clinicaltrials.gov) -  Sep 14, 2021   
    P1b/2,  N=200, Recruiting, 
    Although the combination of cisplatin and cetuximab did not induce apoptosis of cisplatin-resistant cells, it may be useful in treating oral cancer patients with cisplatin resistance given that it controls cell motility and EMT-related proteins. Not yet recruiting --> Recruiting
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, motolimod (VTX 2337) / BMS
    Journal, Combination therapy, IO biomarker:  The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent. (Pubmed Central) -  Sep 9, 2021   
    Depletion of CD4+ T cells, CD8+ T cells and NK cells were all able to abolish the anti-tumor effect of VTX-2337+ cetuximab. Altogether, VTX-2337 remains promising as an adjuvant for cetuximab-based therapy however patients with high TLR8 expression may be more likely to derive benefit from this drug combination compared to patients with low TLR8 expression.
  • ||||||||||  glecirasib (JAB-21822) / Jacobio Pharma
    Enrollment open, Combination therapy, Monotherapy, Metastases:  JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation (clinicaltrials.gov) -  Sep 8, 2021   
    P1/2,  N=100, Recruiting, 
    Altogether, VTX-2337 remains promising as an adjuvant for cetuximab-based therapy however patients with high TLR8 expression may be more likely to derive benefit from this drug combination compared to patients with low TLR8 expression. Not yet recruiting --> Recruiting
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal:  Targeted Therapy as a Potential De-Escalation Strategy in Locally Advanced HPV-Associated Oropharyngeal Cancer: A Literature Review. (Pubmed Central) -  Sep 8, 2021   
    These findings indicate the need for a better understanding of OPSCC biology in the design of rational therapeutic strategies and the development of novel, OPSCC-targeted therapies that are safe and can improve the therapeutic index of standard therapies. In this review, we summarize ongoing research on mechanism-based inhibitors in OPSCC, beginning with the salient molecular features that modulate tumorigenic processes and response, then exploring pharmacological inhibition and pre-clinical validation studies of candidate targeted agents, and finally, summarizing the progression of those candidates in the clinic.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    A Rare Case of Menetrier's Disease (Shoreline Exhibit Hall) -  Sep 8, 2021 - Abstract #ACG2021ACG_1494;    
    Middle third of the esophagus demonstrating resolution of mass after treatment with Cetuximab.F. Polyp of the sigmoid colon demonstrated on colonoscopy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Hurry Up and Treat, a Deadly Variant: Metastatic Basaloid Squamous Cell Carcinoma (Shoreline Exhibit Hall) -  Sep 8, 2021 - Abstract #ACG2021ACG_912;    
    Case Description/ A 69 year old male with medical history of chronic liver disease due to alcohol cirrhosis and Hepatitis C (treatment naïve), left pharyngeal/tonsillar HPV+ squamous cell carcinoma s/p radiotherapy plus Cetuximab who had follow-up PET-CT after completion of therapy with findings of hypermetabolic lesion on rectosigmoid junction area consulted for sigmoidoscopy...With this, we hope to raise awareness of this rare type of SCC its aggressiveness, and how it may present with symptoms of liver decompensation. In view that in most cases it may present as stage III to IV, the overall survival rate and patient prognosis is unfavorable.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    A Case of Ménétrier's Disease Treated With Cetuximab (Shoreline Exhibit Hall) -  Sep 8, 2021 - Abstract #ACG2021ACG_223;    
    4: Endoscopic ultrasound demonstrating marked polypoid thickening of the gastric wallFig. 5: Photomicrograph showing proliferation of foveolar epithelium resulting in elongated, branched pits and dilated glands
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
    Review, Journal:  Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion. (Pubmed Central) -  Sep 8, 2021   
    High-quality evidence is limited, but this strategy is often used in routine clinical practice in the absence of alternative therapies especially in patients with good performance status. (4) To use specific treatments for very selected populations, such as trastuzumab/lapatinib in mCRC human epidermal growth factor receptor 2-positive, immunotherapy in microsatellite instability, intrahepatic therapies in limited disease or primarily located in the liver, although the main recommendation is to include patients in clinical trials.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Journal:  Risk factors for severe radiation-induced oral mucositis in patients with oral cancer. (Pubmed Central) -  Sep 7, 2021   
    This study describes the risk factors of severe radiation-induced oral mucositis in oral cancer patients and shows the possibility of risk reduction by pilocarpine. This information could help patients avoid painful mucositis.